TCM combined with EGFR-TKI treatment prolonged progression-free survival (PFS) in patients with NSCLC who were harboring EGFR mutations and caused no adverse effects (Jiao et al., 2019; Tang et al., 2019). This evidence concerns the gene EGFR and non-small cell lung carcinoma.